Correlation between HMGB1 expression and drug resistance and prognosis in patients with bladder urothelial carcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Low expression of High Mobility Group Box-1 (HMGB1) mRNA in bladder urothelial carcinoma patients indicates a better prognosis. HMGB1 is highly expressed in tumors, and its inhibition slows cancer cell proliferation.
Area Of Science
- Oncology
- Molecular Biology
- Biochemistry
Background
- High Mobility Group Box-1 (HMGB1) is implicated in various cancers.
- Understanding HMGB1's role in bladder urothelial carcinoma (BUC) is crucial for prognosis.
Purpose Of The Study
- To investigate the association between circulating HMGB1 mRNA expression and BUC patient characteristics and prognosis.
- To evaluate the impact of HMGB1 expression on tumor growth and response to chemotherapy.
Main Methods
- Real-time fluorescence quantitative PCR to measure circulating HMGB1 mRNA levels.
- Western Blot to assess HMGB1 protein expression in tissues.
- In vitro studies to evaluate HMGB1 knockdown effects on cell proliferation.
- 3-year post-surgery follow-up for survival analysis.
Main Results
- Circulating HMGB1 mRNA levels were not significantly different across various clinical pathological characteristics.
- Lower HMGB1 mRNA expression correlated with longer survival in BUC patients.
- HMGB1 was upregulated in BUC tissues, and its inhibition suppressed tumor cell proliferation.
- Chemotherapy drugs effectively inhibited BUC cell proliferation.
Conclusions
- HMGB1 is highly expressed in BUC and its inhibition hinders tumor cell proliferation.
- Circulating HMGB1 mRNA levels serve as a prognostic biomarker for BUC.
- Low HMGB1 mRNA expression is associated with improved patient survival.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
